ReviewFrontiers in cell and developmental biology2025
Mechanisms of rapid tumor progression after insufficient radiofrequency ablation of hepatocellular carcinoma.
Review in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatocellular carcinoma (HCC) is one of the most prevalent malignant tumors globally, characterized by high incidence and mortality rates. Radiofrequency ablation (RFA) is a widely adopted primary ablative therapy for HCC, playing a pivotal role in the management of small HCC and unresectable lesions. However, a subset of HCC patients experiences rapid tumor recurrence and progression following RFA. Objective: This review aims to summarize the mechanisms underlying rapid tumor progression after RFA for hepatocellular carcinoma, thereby providing a theoretical foundation and future research directions for preventing post-ablation recurrence and progression. Methods: A systematic review of the literature was performed to synthesize current evidence on the mechanisms of tumor recurrence and progression following RFA for HCC, and to discuss corresponding preventive and therapeutic strategies. Results: Insufficient radiofrequency ablation (IRFA) is a significant driver of tumor recurrence and progression. Post-ablation relapse is not a simple process of residual cell repopulation but a multifaceted vicious cycle initiated by ablation stress. The core mechanism involves residual tumor cells surviving within a synergistic, pro-tumorigenic microenvironment characterized by thermal injury, hypoxia, inflammation, non-coding RNA dysregulation, epigenetic alterations, and immunosuppression. This hostile niche exerts intense selective pressure, activating a complex molecular cascade that promotes cell survival, immune evasion, and malignant proliferation, ultimately driving rapid progression and invasive recurrence. Conclusion: IRFA for hepatocellular carcinoma leaves behind residual tumor cells that acquire aggressive malignant phenotypes through diverse biological mechanisms, driving disease recurrence and progression. Enhancing the precision of ablation techniques and developing integrated, multi-modal treatment strategies are promising avenues to suppress post-ablation recurrence and improve long-term patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.